Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma	Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 2	2026-02-02		NCT05180097

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Australasian Leukaemia and Lymphoma Group	6
Canadian Cancer Trials Group	73
Merck Sharp & Dohme LLC	650
Pfizer	431

18 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Allan Blair Cancer Centre	Regina	Canada	76
Arthur J.E. Child Comprehensive Cancer Centre	Calgary	Canada	45
Austin Hospital	Heidelberg	Australia	37
BCCA - Vancouver	Vancouver	Canada	22
CIUSSS de l'Estrie - Centre hospitalier	Sherbrooke	Canada	7
Concord Repatriation General Hospital	Concord	Australia	39
Dr. H. Bliss Murphy Cancer Centre	St. John's	Canada	4
Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Canada	60
London Health Sciences Centre Research Inc.	London	Canada	13
Ottawa Hospital Research Institute	Ottawa	Canada	46
QEII Health Sciences Centre	Halifax	Canada	11
Royal Adelaide Hospital	Adelaide	Australia	132
Shoalhaven Cancer Care Centre	Nowra	Australia	2
Sir Charles Gairdner Hospital	Perth	Australia	14
The Jewish General Hospital	Montreal	Canada	20
The Research Institute of the McGill University	Montreal	Canada	10
University Health Network	Toronto	Canada	52
Wollongong Hospital	Wollongong	Australia	29